Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies

1. Matos E, Cufer T. Adjuvant treatment of breast cancer with transtuzumab. Radiol Oncol 2007; 41: 115-22.10.2478/v10019-007-0020-ySearch in Google Scholar

2. Rajer M, Majdic E. Locoregional control and survival after conserving therapy. Radiol Oncol 2006; 40: 23-8.Search in Google Scholar

3. Kaufmann M, Hortobagy GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24: 1940-9.10.1200/JCO.2005.02.618716622270Search in Google Scholar

4. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J ClinOncol 2006; 24: 1037-44.10.1200/JCO.2005.02.691416505422Search in Google Scholar

5. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European cooperative trial in operable breast cancer. JClin Oncol 2009; 27: 2474-81.10.1200/JCO.2008.19.256719332727Search in Google Scholar

6. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer InstMonogr 2001; 30: 96-102.10.1093/oxfordjournals.jncimonographs.a00346911773300Search in Google Scholar

7. von Minckwitz G, Blohmer JU, Raab G, Loehr A, Gerber B, Heinrich G, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16: 56-63.10.1093/annonc/mdi00115598939Search in Google Scholar

8. Alvarez RH, Hortobagyi GN. Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design. BreastCancer Research Treat 2010; 124: 701-5.10.1007/s10549-010-1212-520953832Search in Google Scholar

9. Untch M, von Minkwitz G. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Research 2009; 11: 203-10.10.1186/bcr2227268893819344488Search in Google Scholar

10. von Minkwitz G, Raab G, Caputo A, Schuette M, Hilfrich J, Blohmer JU, et al. Doxorubicin with Cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23: 2676-85.10.1200/JCO.2005.05.07815837982Search in Google Scholar

11. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J NatlCancer Inst 2009; 101: 736-50.10.1093/jnci/djp082268455319436038Search in Google Scholar

12. Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology 2010; 79: 324-30.10.1159/00032219221430399Search in Google Scholar

13. Lips EH, Mulder L, de Ronde JJ, Mandjes IAM, Vincent A, Vrancken Peeters MT, et al. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat 2012; 131: 827-36.10.1007/s10549-011-1488-021472434Search in Google Scholar

14. von Minkwitz G, Untch M, Nuesch E, Loibi S, Kaufmann M, Kuemmel S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125: 145-56.10.1007/s10549-010-1228-x21042932Search in Google Scholar

15. Lombardi D, Scalone S, Crivellari D, Magri MD, La Mura N, Miolo G, et al. Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study. Tumori 2010; 96: 229-33.10.1177/030089161009600207Search in Google Scholar

16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.10.1093/jnci/92.3.20510655437Search in Google Scholar

17. Common Toxicity Criteria, Version 2.0. National Institutes of Health, National Cancer Institute. Available. http://www.eortc.be/services/doc/ctc/ ctcv20_4-30-992.pdfSearch in Google Scholar

18. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Science Publications; 1987.Search in Google Scholar

19. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau S-W, Broglio K, Theriault RL, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005; 23: 41-8.10.1200/JCO.2005.03.11115625359Search in Google Scholar

20. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, et al. Sequential preoperative and postoperative docetaxel added to preoperative Doxorubicin plus Cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Prroject Protocol B-27. J Clin Oncol 2006; 24: 2019-27.10.1200/JCO.2005.04.166516606972Search in Google Scholar

21. Chia YH, Ellis MJ, Ma CX. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer 2010; 103: 759-64.10.1038/sj.bjc.6605845296662920700118Search in Google Scholar